NKG2A, a New Kid on the Immune Checkpoint Block

Cell

Volumn 175, Issue 7, 2018, Pages 1720-1722

  Haanen, John B ^a   Cerundolo, Vincenzo ^b  

^a The Netherlands Cancer Institute   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; MONALIZUMAB; NATURAL KILLER CELL RECEPTOR NKG2A; PEPTIDE VACCINE; CANCER VACCINE;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LYMPHOMA; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 85057581994     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.11.048     Document Type: Short Survey

References (10)

1. André P., Denis, C., Soulas, C., Bourbon, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. Anti-NKG2A monalizumab promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175 (2018), 1731–1743 this issue.
2. Braud, V.M., Allan, D.S., O'Callaghan, C.A., Söderström, K., D'Andrea, A., Ogg, G.S., Lazetic, S., Young, N.T., Bell, J.I., Phillips, J.H., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998), 795–799.
3. + T cell responses restricted by major histocompatibility complex E. Science 351 (2016), 714–720.
4. Kochan, G., Escors, D., Breckpot, K., Guerrero-Setas, D., Role of non-classical MHC class I molecules in cancer immunosuppression. OncoImmunology, 2, 2013, e26491.
5. Levy, E.M., Bianchini, M., Von Euw, E.M., Barrio, M.M., Bravo, A.I., Furman, D., Domenichini, E., Macagno, C., Pinsky, V., Zucchini, C., et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int. J. Oncol. 32 (2008), 633–641.
6. Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J.J., Tran, H., Kim, Y.U., Haymaker, C., Bernatchez, C., Curran, M., Zecchini Barrese, T., Rodriguez Canales, J., Wistuba, I., Li, L., Wang, J., van der Burg, S.H., Melief, C.J., Glisson, B., Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol., 2018, 10.1001/jamaoncol.2018.4051 Published online September 27, 2018.
7. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.F., Testori, A., Grob, J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364 (2011), 2517–2526.
8. Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C.P., Caramia, F., Salgado, R., Byrne, D.J., Teo, Z.L., Dushyanthen, S., et al., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24 (2018), 986–993.
9. van Montfoort, N., Borst, L., Korrer, M.J., Sluijter, M., Marijt, K.A., Santegoets, S.J., van Ham, V.J., Ehsan, I., Charoentong, P., André P., et al. NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines. Cell 175 (2018), 1744–1755 this issue.
10. Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 377 (2017), 1345–1356.